Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes

BACKGROUND: Stopping nucleos(t)ide analogues (NA) after hepatitis B e antigen (HBeAg) seroconversion is associated with high relapse rates in Asian patients, but data in Caucasian cohorts are scarce. Clinical course, outcomes and immunological aspects of chronic hepatitis B infections differ substan...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Aliment Pharmacol Ther
Glavni autori: Van Hees, S., Bourgeois, S., Van Vlierberghe, H., Sersté, T., Francque, S., Michielsen, P., Sprengers, D., Reynaert, H., Henrion, J., Negrin Dastis, S., Delwaide, J., Lasser, L., Decaestecker, J., Orlent, H., Janssens, F., Robaeys, G., Colle, I., Stärkel, P., Moreno, C., Nevens, F., Vanwolleghem, T., Van Hees, Stijn, Bourgeois, Stefan, Van Vlierberghe, Hans, Sersté, Thomas, Francque, Sven, Michielsen, Peter, Sprengers, Dirk, Reynaert, Hendrik, Henrion, Jean, Negrin‐Dastis, Sergio, Delwaide, Jean, Lasser, Luc, Decaestecker, Jochen, Orlent, Hans, Janssens, Filip, Robaeys, Geert, Colle, Isabelle, Stärkel, Peter, Moreno, Christophe, Nevens, Frederik, Vanwolleghem, Thomas
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Fatal Outcomes from Stopping Nucleoside Analogues in Hepatitis B
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5900846/
https://ncbi.nlm.nih.gov/pubmed/29498078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14560
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items